Love it, but…I think the ‘months needing treatment’ multiplier is a bit exuberant?
I can’t remember where I read this (so I could be wrong) but the Japan sales figures showed a high percentage of sales coming from new users, which to me indicated a low percentage of sales coming from repeat prescriptions. Either way my impression was that the product wasn’t being used as a daily thing.
Having said that I know Japan ain’t the US and there appears to be very different sales strategies. Would love it if someone with a better memory could confirm/deny my thoughts on the Japan repeat prescription numbers.
Love it, but…I think the ‘months needing treatment’ multiplier...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.8¢ |
Change
0.008(2.03%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.5¢ | 37.5¢ | $1.473M | 3.891M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 656624 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 388407 | 18 |
View Market Depth
| Last trade - 15.17pm 29/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |